This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Third View: Discussing Kymera Therapeutic's Phase 1 results for KT-474, an orally bioavailable heterobifunctional degrader for hidradenitis suppurativa and atopic dermatitis patients.
Ticker(s): KYMRWho's the expert?
Institution: ClearSkin Dermatology
- Medical Director of ClearSkin Dermatology
- Manages 400 patients with AD and HS
Interview GoalThis conversation will focus on the current treatment landscape and potential use of KT-474 for patients with HS and AD
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
